BTIG Maintains Buy on Globus Medical, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has maintained a Buy rating on Globus Medical (NYSE:GMED) and increased the price target from $60 to $63.

May 08, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman reaffirmed a Buy rating on Globus Medical and raised the price target to $63 from $60.
The increase in price target by a reputable analyst like Ryan Zimmerman suggests a positive outlook on Globus Medical's stock, likely due to strong company fundamentals or market position. This endorsement can boost investor confidence, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100